OREANDA-NEWS. Major progress towards orthopaedics approvals: Tissue Regenix is now in the commercialisation phase having validated its dCELL® technology to produce 'like-for-like' tissue specific, structure-preserving scaffolds for use in multiple clinical settings. DermaPure has started well in the US for treating chronic wounds and traction will increase now that it is widely reimbursed by Medicare providers. But newsflow in the next 12 months is likely to be dominated by the approval and launch of the orthopaedics products for meniscal and tendon repairs. Despite short term monthly cashburn of c.?1m, TRX is building long term value, evidenced by 32p NPV driven by three core product areas.

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.